Baseline Anemia Is Not a Predictor of All-Cause Mortality in Outpatients With Advanced Heart Failure or Severe Renal Dysfunction Results From the Norwegian Heart Failure Registry by Waldum, Bård et al.
Journal of the American College of Cardiology Vol. 59, No. 4, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00CLINICAL RESEARCH Heart Failure
Baseline Anemia Is Not a Predictor
of All-Cause Mortality in Outpatients With
Advanced Heart Failure or Severe Renal Dysfunction
Results From the Norwegian Heart Failure Registry
Bård Waldum, MD,*† Arne S. Westheim, MD, PHD,‡ Leiv Sandvik, PHD,§ Berit Flønæs, RN,
Morten Grundtvig, MD,¶ Lars Gullestad, MD, PHD,# Torstein Hole, MD, PHD,**††
Ingrid Os, MD, PHD†
Oslo, Sandvika, Lillehammer, Trondheim, and Ålesund, Norway
Objectives The aim of this study was to evaluate the prognostic impact of anemia in outpatients with chronic heart failure
attending specialized heart failure clinics and specifically to investigate its prognostic utility in patients with se-
vere renal dysfunction or advanced heart failure.
Background Anemia is an independent prognostic marker in patients with heart failure. The effect of anemia on mortality
decreases with increasing creatinine levels.
Methods Multivariate Cox regression analyses were used to investigate the prognostic effect of anemia in 4,144 patients
with heart failure from 21 outpatient heart failure clinics in Norway. Severe renal failure was defined as esti-
mated glomerular filtration rate 45 ml/min/1.73 m2 and advanced heart failure as New York Heart Associa-
tion functional classes IIIb and IV.
Results Baseline anemia was present in 24% and was a strong predictor of all-cause mortality (adjusted hazard ratio
[HR]: 1.30, 95% CI: 1.09 to 1.56, p  0.004). Baseline anemia did not predict mortality in the 752 patients with
severe renal dysfunction (adjusted HR: 1.08, 95 % CI: 0.77 to 1.51, p  0.662) and the 528 patients with ad-
vanced heart failure (adjusted HR: 0.87, 95% CI: 0.56 to 1.34, p  0.542). In the 1,743 patients who attended
subsequent visits, sustained anemia independently predicted worse prognosis (adjusted HR: 1.47, 95% CI: 1.10
to 1.94, p  0.008), whereas transient and new-onset anemia did not.
Conclusions According to our study, baseline anemia was not an independent predictor of all-cause mortality in outpatients with
heart failure and accompanied severe renal dysfunction or advanced heart disease. Sustained anemia after optimiz-
ing heart failure treatment might imply worse prognosis independently of renal function and New York Heart Associa-
tion functional class. (J Am Coll Cardiol 2012;59:371–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.864Anemia is prevalent among patients with heart failure
(1). Renal dysfunction, activation of neurohormonal and
inflammatory responses, drug effects, and bone marrow
hyporesponsiveness all seem to contribute to the devel-
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2011, accepted October 3, 2011.opment of anemia in patients with heart failure (2,3).
Estimates of the actual prevalence of anemia among
patients with heart failure vary widely due to differences
in the definition of anemia and in investigated patient
populations. Most studies have identified prevalence of
anemia 20% (4).
Numerous studies have demonstrated a strong rela-
tionship between anemia and mortality in populations
with heart failure (5,6). It is apparent from a recent
review (5) that most studies were performed in selected
study populations or among hospitalized patients. Epi-
demiological data suggest an inverse relationship between
serum creatinine level and the influence of anemia on
mortality in heart failure patients, because the effect of
anemia on mortality declines with increasing serum
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cate that anemia is not an inde-
pendent risk factor of mortality
in all subgroups of heart failure
patients.
Our aims were to evaluate
the prognostic impact of ane-
mia both at baseline and sus-
tained during follow-up on all-
cause mortality in patients with
chronic heart failure attending
specialized outpatient heart
failure clinics. Furthermore, we
wanted to evaluate the prog-
nostic effect of anemia in sub-
groups of high-risk heart failure
patients.
Methods
The Norwegian Heart Failure
Registry. The Norwegian Heart
Failure Registry was initiated in
October 2000 with the intent to
collect data on outpatients at-
tending office visits in heart fail-
ure clinics (7). The registry originally included 10 hospitals.
By March 2008 the number of participating units had
gradually increased to 24 clinics situated in all regions in
Norway; at that time 5,030 patients were included. Cardi-
ologists in cooperation with specially trained nurses run the
heart failure outpatient clinics. Patients with heart failure of
any etiology, New York Heart Association (NYHA) func-
tional class I to IV, diagnosed clinically according to
guidelines from the European Society of Cardiology (8),
were enrolled consecutively in the heart failure clinics. At
the first visit (baseline) medical history, physical examina-
tion, echocardiography, laboratory results, and the medical
management of heart failure were registered. Visit 2 was
recorded, after adjustment of medical therapy and having
patients undergo an educational program. If required, ad-
ditional clinical visits could be scheduled to ensure optimi-
zation of therapy before Visit 2. Finally, Visit 3 was planned
to occur 6 months after Visit 2. Mortality data were
retrieved from the Norwegian death registry kept by Statis-
tics Norway; by March every year, the current database was
updated with respect to mortality data by March 2008. Both
baseline hemoglobin level and mortality data were available
in 4,144 patients from 21 hospitals, who were included in
the baseline analyses. Less than 50% (n  1,972) completed
all planned visits in the heart failure registry, of whom 1,743
patients had registration of hemoglobin levels at both
baseline and Visit 3.
All participants provided written informed consent before
inclusion in the database. Only unidentifiable data were
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
BMI  body mass index
BNP  brain natriuretic
peptide
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
IHD  ischemic heart
disease
NYHA  New York Heart
Association
OR  odds ratio
RAAS  renin-angiotensin-
aldosterone system
WHO  World Health
Organizationentered in the database. Permission for this analysis wasgranted from the National Data Inspectorate and the
Regional Committee of Medical and Health Research
Ethics.
Definitions. Anemia was defined according to the World
Health Organization (WHO) guidelines as blood hemoglo-
bin below 13.0 g/dl in men and below 12 g/dl in women (9).
Hemoglobin levels were analyzed at the local heart failure
clinics. Baseline anemia was defined as anemia at Visit 1.
Sustained anemia was defined as anemia at both Visit 1 and
Visit 3. Transient anemia was defined as anemia at baseline
but not at the last visit, whereas patients with new-onset
anemia were not anemic at baseline but anemic at the last
visit.
Heart failure was categorized as NYHA functional class I
to IV on the basis of symptoms during varying activities.
The NYHA functional class III was divided into class IIIa
and IIIb; patients in NYHA functional class IIIb were not
able to cover 325 m during the 6-min walk test performed
at the local heart failure clinics. Advanced heart failure was
defined prospectively as NYHA functional class IIIb or IV.
Renal function was assessed as glomerular filtration rate
was estimated on the basis of the simplified Modification of
Diet in Renal Disease prediction equation and expressed as
estimated glomerular filtration rate (eGFR) as follows:
eGFR (ml/min/1.73m2)
 186.3 · (serum creatinine[mg/dl])1.154
· (age)0.203 · 0.742(female) · 1.212(black)
Renal function was stratified according to glomerular filtration
rate limits in the Kidney Disease Outcome Quality Initiative
guidelines (10). Patients with eGFR 60 ml/min/1.73 m2
were stratified into chronic kidney disease (CKD) stage 1 and
2, despite lack of data on renal damage. Severe renal dysfunc-
tion was defined arbitrarily as eGFR 45 ml/min/1.73 m2,
ecause the number of patients with CKD stage 4 and 5 were
ow. This was done prospectively to add statistical power to the
evere renal failure group.
A high proportion of the population was already treated
t baseline with diuretics, renin-angiotensin-aldosterone
ystem (RAAS) blocking drugs, and beta-blockers. To
ifferentiate between treatment intensity, daily dose equiv-
lents were calculated. Daily doses of loop diuretics were
xpressed in furosemide equivalents (bumetanide 1 mg 
urosemide 40 mg). Doses of angiotensin-converting enzyme
nhibitors (ACEI) were expressed as enalapril equivalents/day
captopril 5 mg  ramipril 0.5 mg  lisinopril 1 mg 
nalapril 1 mg). The ACEIs were more frequently used than
ngiotensin receptor blockers (ARBs), and patients using
RBs were excluded when analyzing ACEI daily dose in the
aseline characteristics. Daily dose of beta-blocker was ex-
ressed as metoprolol equivalents (bisoprolol 1 mg carvedilol
mg  atenolol 10 mg  metoprolol 20 mg).
Vascular disease was defined as previous stroke and/orperipheral arterial disease. The diagnosis of ischemic heart
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January 24, 2012:371–8 Anemia in Outpatients With Heart Failuredisease (IHD) as the cause of heart failure was based on
clinical evaluation at the time of inclusion.
Statistical analysis. Continuous variables were presented
as mean  SD. Categorical data were presented as percent-
ages. Student t test was used for continuous data when
omparing the anemia and non-anemia groups. For the
ame purpose, chi-square test was used to compare categor-
cal data. Analysis of variance was used to compare hemo-
lobin levels in different stages of CKD and NYHA
unctional class. Cox regression analyses were used to
etermine the association of anemia with all-cause mortal-
ty. Univariate Cox regression analyses were performed, and
tatistically significant predictors of mortality at baseline
ere entered into the multivariate Cox regression model to
easure the multiple adjusted hazard ratio (HR) of baseline
nemia on all-cause mortality. In addition to baseline
nemia, statistically significant independent predictors of
ortality at baseline were male sex, age, NYHA functional
lass, eGFR, body mass index (BMI), diabetes mellitus, and
oop diuretic daily dose. These variables were entered in the
ollowing Cox models for multivariate adjustment, baseline
alues were used when analyzing baseline anemia, and last
isit values were used when analyzing follow-up data. All
ncluded variables in the multivariate analyses are reported
n the Results section.
A multivariate Cox regression model with hemoglobin as
continuous variable instead of the dichotomous variable
nemia was performed in patients completing all visits to
valuate the prognostic implication of degree of anemia.
Kaplan-Meier plots were used to describe survival during
he observation period in different patient groups. Log-rank
tatistics was used to identify differences between groups.
A logistic regression model was used to investigate
ifferences between patients who attended all planned visits
ith those who did not. Independent predictors of mortality
t baseline were entered in the model to differentiate the 2
roups.
Brain natriuretic peptide (BNP) and pro-BNP were not
ncluded in the multivariate analyses due to low number of
alid data. IHD was the dominant cause of heart failure and
as evaluated against all other etiologies of heart failure as
group.
The assumption of linearity of the logit of the outcome
or continuous variables entered into the logistic models was
hecked (11). Serum sodium and systolic blood pressure did
ot meet the assumption of linearity; they were dichoto-
ized with cutoffs near mean values. Likewise, ejection
raction did not meet the assumptions; here we dichoto-
ized with a natural cutoff of ejection fraction 40%.
nalapril equivalent dose did not meet the assumption of
inearity of the logit to outcome. The dichotomous variable
se of ACEI or ARB, both blocking the RAAS, was
ntered in the multivariate logistic analysis. Spearman’s
orrelation test was used to check for colinearity; no pair of
ndependent variables was found to correlate to such a
egree that they could not be simultaneously entered to- pether in the regression analyses (all coefficients0.43). For
ach Cox model the proportional hazard assumption was
hecked and found to be adequately met (11). Differences in
R between patients with severe renal failure and advanced
eart failure compared with the rest of the heart failure
opulation were checked with interaction analysis by prod-
ct terms. Analyses on other potential interactions in the
ox analyses were performed with respect to age, sex, and
jection fraction; no significant interactions were found.
evel of significance was set at 0.05. Analyses were per-
ormed with SPSS statistical software (version 15.0, SPSS,
nc., Chicago, Illinois).
esults
total of 4,144 patients were included in the analyses of the
aseline characteristics (Table 1). The majority of patients
ere men, and 55% were older than 70 years. At baseline
ean hemoglobin concentration was 13.8  1.7 g/dl.
requency of anemia defined by WHO criteria was 24.0%.
evere renal dysfunction (eGFR 45 ml/min/1.73 m2) was
resent in 752 patients (18.2%), of whom 31.0% had anemia
mean hemoglobin 12.9  1.7 g/dl). Severe heart failure
NYHA functional class IIIb or IV) was present in 528
atients (13.0%), of whom 32.8% had anemia (mean hemo-
lobin 13.3  1.8 g/dl).
Multivariate logistic regression model with baseline ane-
ia as the dependent variable identified a number of
ariables independently associated with anemia (Table 2).
nemia was strongly associated with both renal function
p  0.001) and heart failure severity defined by NYHA
functional class (p  0.001). Figure 1 describes the additive
effect of worsening renal function and worsening NYHA
functional class on hemoglobin levels.
During the median follow-up time of 28 months (range
0 to 94 months), 1,166 patients (28.1 %) died. Baseline
anemia was a strong predictor of all-cause mortality (Fig. 2).
Median survival in the whole population was 82 months.
Patients with anemia had a median survival of 50 months
versus 89 months in patients without anemia. Crude HR of
anemia was 1.87 (95% confidence interval [CI]: 1.66 to
2.11; p  0.001). After multivariate adjustment anemia
remained a strong predictor of all-cause mortality, with HR
of 1.30 (95% CI: 1.09 to 1.56; p  0.004) (Table 3).
Patients with severe renal dysfunction (eGFR45 ml/min/
.73 m2) and advanced heart failure (NYHA functional class
IIb or IV) were analyzed separately to investigate the prog-
ostic impact of baseline anemia in patients with the highest
ortality risk. By interaction analysis, HR of baseline anemia
as significantly lower in patients with advanced heart failure
ompared with the rest of the heart failure population (HR:
.23 vs. 1.96, p 0.002), and anemia was not an independent
rognostic variable of all-cause mortality in the 528 patients
ith NYHA functional class IIIb or IV (adjusted HR: 0.86;
5% CI: 0.56 to 1.33, p 0.495) (Table 4). Likewise, the 752
atients with eGFR 45 ml/min/1.73 m2 had significantly
rss; RAA
blood p
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eGFR (HR: 1.39 vs. 1.80, p  0.022), and anemia was not
an independent predictor of all-cause mortality in these
patients (adjusted HR: 1.08; 95% CI: 0.77 to 1.51; p 
0.662) (Table 4).
Further interaction analyses did not show any difference
in the prognostic information of baseline anemia in patients
with mild renal dysfunction (eGFR 45 ml/min/1.73 m2
and 60 ml/min/1.73 m2) compared with patients without
enal dysfunction (eGFR 60 ml/min/1.73 m2) (HR: 1.50
Baseline Characteristics of 4,144 Outpatients WOverall and by Anemia StatusTable 1 B seline Characteristics of 4,144 OOverall and by Anemia Status
Characteristic
All Patients
(N  4,144) Val
Demographic data
Age (yrs) 70.2 11.9
Male 70.5
Smoking 15.1
Medical history
IHD 55.1
Diabetes mellitus 19.9
COPD 16.9
Vascular disease 15.3
Physical exam
SBP (mm Hg) 126.2 22.7
EF (%) 33.0 12.0
BMI (kg/m2) 26.1 4.9
NYHA functional class
I 4.2
II 43.1
IIIa 39.7
IIIb 11.4
IV 1.6
Laboratory data
GFR (ml/min/1.73 m2) 65.9 23.2
Hemoglobin (g/dl) 13.8 1.7
Se-BNP (pg/ml) 434 676
Se-ProBNP (pg/ml) 2,124 3,274
Se-sodium (mmol/l) 139.8 3.3
Se-uric acid (mmol/l) 463 133
Se-cholesterol (mmol/l) 4.8 1.3
Current medication
RAAS blockade use 88.1
ACEi dose/day (mg) 10.7 9.2
Loop diuretic dose/day (mg) 60.0 61.3
Beta-blocker use 81.1
Beta-blocker dose/day (mg) 67.1 64.2
Spironolactone use 23.9
CCB use 8.2
Warfarin use 47.2
ASA use 44.2
Statin use 51.2
Values are mean  SD or %. Anemia defined by World Health Organi
ACEi dose/day  daily enalapril equivalent dose; beta-blocker dose/d
mass index; BNP brain natriuretic peptide; CCB calcium channel blo
daily furosemide equivalent dose; EF ejection fraction; GFR glomerula
natriuretic peptide; NYHA  New York Heart Association functional cla
angiotensin receptor blockers; Se serum level analysis; SBP systolic[95% CI: 1.20 to 1.86] vs. 1.87 [95% CI: 1.52 to 2.30]; p 0.167). Likewise no interaction was found between NYHA
functional classes IIIa and I to II (HR: 1.92 [95% CI: 1.55
to 2.38] vs. 1.85 [95% CI: 1.55 to 2.20]; p  0.836). The
prognostic impact of baseline anemia did not differ with
respect to age, sex, or ejection fraction.
Less than 50% (n  1,972) completed all 3 visits in the
heart failure registry, of whom 1,743 patients had valid data
on hemoglobin levels at the last visit. Baseline anemia was
present in 361 patients (21.3%) in this subgroup of patients.
Sustained anemia defined as anemia both at baseline and the
eart Failure:tien s With Heart Failure:
a (%)
No Anemia
(n  3,151)
Anemia
(n  993) p Value
69.1 12.1 73.8 10.7 0.001
68.8 75.7 0.001
17.1 11.8 0.001
52.2 64.4 0.001
17.9 26.4 0.001
17.1 16.2 0.534
13.8 20.9 0.001
126.7 22.3 124.4 23.8 0.006
32.6 11.9 34.3 12.5 0.001
26.4 4.9 24.9 4.5 0.001
0.001
4.9 2
45.2 36.6
38.4 43.7
10.2 15.1
1.3 2.7
68.6 22.6 57.3 2.9 0.001
14.5 1.3 11.6 0.9 0.001
402 675 531 674 0.026
1,969 3,051 2,696 3,947 0.005
139.9 3.2 139.4 3.6 0.001
457 131 482 140 0.001
4.9 1.3 4.4 1.2 0.001
89.7 82.9 0.001
11.0 9.4 9.8 8.7 0.001
54.6 52.8 77.0 80.4 0.001
81.2 80.4 0.478
67.7 64.3 65.0 63.6 0.249
24.0 23.3 0.614
7.6 9.9 0.021
48.2 44.1 0.023
43.2 47.6 0.014
50.7 52.9 0.226
WHO) criteria.
ily metoprolol equivalent dose; ASA  acetylsalicylic acid; BMI  body
PD chronic obstructive pulmonary disease; Loop diuretic dose/day
on rate; IHD ischemic heart disease; NT-proBNPN-terminal pro-brain
S blockade  use of angiotensin-converting enzyme inhibitors and/or
ressure; Vascular disease earlier stroke or peripheral vascular disease.ith Hu pa
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January 24, 2012:371–8 Anemia in Outpatients With Heart Failurecompleting all visits), whereas in 41.8% of patients with
initial anemia (n  151), anemia had resolved at Visit 3.
ew-onset anemia was observed in 195 patients (14.2% of
atients who were non anemic at baseline). Prevalence of
nemia at Visit 3 was 23.3%.
In the patients who completed all visits, baseline anemia
ontinued to be an independent predictor of mortality (ad-
usted HR: 1.33, 95% CI: 1.07 to 1.66, p  0.011) and
provided the same prognostic information as anemia at the last
visit (adjusted HR: 1.31, 95% CI: 1.03 to 1.68, p  0.030).
Completing all visits was associated with better survival
from the date of the last visit (multiple adjusted HR: 0.67,
Clinical Characteristics andLikelihood of Baseline Anemia by WHO CriteriaTable 2 Clinical Characteristics andLikelihood of Baseline Anemia by WHO Criteria
Clinical Characteristic Wald OR 95% CI p Value
Male 30.20 2.103 1.613–2.742 0.001
Age ( 1 yr) 4.07 1.012 1.000–1.024 0.044
BMI (1 kg/m2) 45.78 0.914 0.890–0.938 0.001
EF 40% 35.81 2.220 1.709–2.882 0.001
RAAS blockade 4.59 0.721 0.535–0.973 0.032
eGFR (1 ml/min) 26.89 0.984 0.978–0.990 0.001
Loop diuretic dose
(1 mg furosemide/day)
12.94 1.003 1.001–1.005 0.001
Se-cholesterol (1 mmol/l) 34.24 0.762 0.695–0.834 0.001
Se- uric acid (1 mmol/l) 5.94 0.999 0.998–1.000 0.015
NYHA (1 U increase) 15.61 1.312 1.147–1.502 0.001
Diabetes mellitus 8.00 1.457 1.122–1.890 0.001
Se- sodium 140 mmol/l 3.39 1.237 1.000–1.530 0.050
Multivariate logistic model. Chi-square 355.1, p  0.001. Only statistically significant variables
were reported in this table. Other variables included in the model were: use of warfarin, use of ASA,
use of CCB, current smoking status, IHD, vascular disease, and SBP 125 mm Hg.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
Figure 1
Mean Baseline Hemoglobin Levels According
to Stages of Renal Function and NYHA Functional
Class in 4,144 Outpatients With Heart Failure
Bars represent mean hemoglobin levels according to stages of estimated glo-
merular filtration rate (eGFR) and New York Heart Association (NYHA) functional
class at the baseline visit in the Norwegian Heart Failure Registry. a95% CI: 0.59 to 0.76, p  0.001). A multivariate logistic
regression model (R2  0.018, p  0.001) identified
patients completing all 3 visits to have less baseline anemia
(odds ratio [OR]: 0.81, p  0.013), lower NYHA func-
tional class (OR: 0.81, p  0.001), higher BMI (1 kg/m2
increase, OR: 1.03, p 0.001) and higher age (1 year older,
OR: 1.01, p  0.008) compared with patients who did not
omplete all planned visits.
Risk of mortality was not significantly different in pa-
ients with transient anemia compared with patients who
ever presented with anemia (crude HR: 0.97, 95% CI: 0.66
o 1.43, p 0.890). New-onset anemia was related to worse
rognosis (crude HR: 1.61, 95% CI: 1.20 to 2.16, p 
.002). After multivariate adjustment new-onset anemia did
Figure 2
Kaplan-Meier Plot, All-Cause Mortality
by Baseline Anemia Defined by WHO Criteria
in 4,144 Outpatients With Heart Failure
Survival plot grouped by anemia state at baseline defined by World Health
Organization (WHO) criteria (i.e., hemoglobin below 13 g/dl in men and below
12 g/dl in women). Log-rank statistics presented.
Multivariate Cox Regression for All-Cause Mortalityby Baseline haracte istics in 4,144 OutpatientsWith H ar Failu e
Table 3
Multivariate Cox Regression for All-Cause Mortality
by Baseline Characteristics in 4,144 Outpatients
With Heart Failure
Wald HR 95% CI p Value
Anemia 7.88 1.296 1.081–1.553 0.005
Male 6.03 1.272 1.050–1.541 0.014
Age (1 yr) 67.59 1.041 1.031–1.051 0.001
NYHA (1 U increase) 29.63 1.343 1.208–1.493 0.001
eGFR (1 ml/min) 9.91 0.992 0.988–0.997 0.002
BMI (1 kg/m2) 5.97 0.976 0.956–0.995 0.015
Diabetes mellitus 11.53 1.400 1.153–1.701 0.001
Loop diuretic dose
(1 mg furosemide/day)
17.23 1.002 1.001–1.003 0.001
Only statistically significant variables were presented in this table. Other variables included in the
model were EF40%, IHD, SBP125 mm Hg, use of RAAS blocking drugs, use of spironolactone,
se of beta-blocking drugs, se- sodium 140 mmol/l, se-cholesterol above mean, se-uric acid
bove mean, and vascular disease.
HR  hazard ratio; other abbreviations as in Table 1.
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Anemia in Outpatients With Heart Failure January 24, 2012:371–8not predict worse outcome compared with patients with no
anemia at any point (adjusted HR: 1.03, 95% CI: 0.73 to
1.46, p  0.848).
Sustained anemia was a strong predictor of mortality
Fig. 3, Table 5). No interactions between sustained anemia
nd advanced heart failure or severe renal dysfunction were
ound in these patients.
Hemoglobin level predicted mortality only in patients
ith sustained anemia (HR: 0.51/1-g/dl increase, 95% CI:
.41 to 0.64, p  0.001), in contrast to patients without
ustained anemia (HR: 0.97/1-g/dl increase, 95% CI: 0.88
o 1.06, p  NS), after adjustment for the variables used in
able 5.
iscussion
aseline anemia was common in this outpatient cohort of
orwegian patients with heart failure. The anemia preva-
HR of Baseline Anemia in 4,144 Outpatients WiTable 4 HR of Baseline Anemia in 4,144 Ou
N
Crude
(95%
All 4,144 1.87 (1.6
NYHA functional class I–IIIa 3,541 1.96 (1.7
NYHA functional class IIIb  IV 528 1.23 (0.9
eGFR 45 ml/min/1.73 m2 3,388 1.80 (1.5
eGFR 45 ml/min/1.73 m2 752 1.39 (1.1
Cox regression all-cause mortality analyses. Separate analyses in pati
sex, age, NYHA functional class, eGFR, BMI, diabetes mellitus, EF 4
drugs, use of spironolactone, se-sodium 140 mmol/l, se-cholestero
Abbreviations as in Tables 1 and 3.
Figure 3
Kaplan-Meier Plot, All-Cause Mortality by
Anemia State at Follow-up in 1,743 Outpatients
Who Completed All Planned Visits in the
Norwegian Heart Failure Registry
Survival plot grouped by anemia state in patients who completed all planned
visits in the Norwegian Heart Failure Registry. Patients with sustained anemia
had anemia at both baseline and the last visit, whereas transient and new-
onset anemia had anemia at only the first or last visit, respectively. Anemia
defined by World Health Organization criteria (i.e., hemoglobin levels below
13 g/dl in men and below 12 g/dl in women). Log-rank statistics presented.lence of 24% is concordant with reports from other outpa-
ient heart failure populations (6). Previous estimates have
aried widely, ranging from 4% up to 61% (6). This
ariation is primarily due to different definitions of anemia
nd differences in study populations. Hospitalized patients
eem to have the highest prevalence of anemia, whereas
linical trial cohorts have the lowest. The WHO definition
f anemia used in the present study is the most frequently
sed definition of anemia in heart failure patients in recent
ears and is the recommended definition (4). Anemia in
omen was defined as hemoglobin levels below 12 g/dl,
ompared with 13 g/dl in men, although the great majority
f female patients were post-menopausal. By interaction
nalyses, the prognostic impact of anemia did not differ
etween men and women, despite the difference in defini-
ion of anemia.
Baseline anemia was strongly associated with mortality in
ur population. Median survival in patients without anemia
as more than 3 years longer than in anemic patients. Our
rude 87% increased all-cause mortality risk among patients
ith anemia was in agreement with findings of a recent
eta-analysis on the topic (5). Thus, anemia—independent
f cause—identified patients with a poor prognosis and
hould alert the clinician to the need for intensified care.
fter adjustment for a large range of confounders, anemia
emained a strong independent prognostic risk factor.
The most striking finding in our study was that baseline
nemia was not an independent predictor of all-cause
ortality in the patients with severe renal dysfunction or the
ost advanced heart failure. Impaired renal function and
ncreasing NYHA functional class both independently pre-
icted more serious prognosis in heart failure patients (12)
nd were closely associated with anemia. Furthermore, these
onditions share many potential etiologies for anemia
1,13). Groenveld et al. (5) found an inverse relationship
etween serum creatinine levels and the effect of anemia on
ortality with meta-regression analysis. The effect on mor-
ality declined with higher serum creatinine levels; this
ight reflect that—at higher creatinine levels—renal dis-
ase accounts for a greater proportion of the mortality risk
han anemia (6). However, Go et al. (14) identified hemo-
lobin level as an independent predictor of outcomes at all
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dysfunction motivated us to perform selected analyses in
patients with the most severe renal dysfunction and most
advanced heart failure. Unfortunately, data regarding an
eventual progression of comorbid conditions were not avail-
able; therefore the reason why baseline anemia did not
predict all-cause mortality in the patients with severe renal
dysfunction and advanced heart failure was not addressed.
Although baseline anemia did not affect mortality in the
patients with advanced heart failure and severe renal dys-
function in our study, our data did not preclude that they
suffer a high symptom burden from their anemia, and
specific anemia treatment could be beneficial with regard to
symptom relief (15–17).
Patients who completed all planned visits had a better
overall prognosis, and our results indicate that these patients
had less-serious disease beyond NYHA functional classifi-
cation, anemia state, age, BMI, and the other prognostic
variables corrected for in our statistical models. Further-
more, the interaction with respect to mortality between
anemia and advanced heart failure and severe renal function
was not present in the patients who completed all planned
visits in the registry. Therefore, patients completing Visit 3
should be regarded as a selected population, not necessarily
representative of outpatients with heart failure. Medication
adherence is shown to be related to survival in heart failure
patients (18), and part of the bad prognosis in patients not
completing all visits in our study might be explained by
nonadherence. Alternatively, they were deprived of the
opportunity to have the treatment of heart failure opti-
mized, because they did not complete all clinical visits.
Anemia was not necessarily persistent; a high proportion
of patients who were anemic at baseline had normal hemo-
globin levels at follow-up. Likewise, new-onset anemia was
prevalent. Patients with transient anemia did not have
significantly higher mortality rates compared with patients
without anemia at any visit. Our data are supported by Tang
et al. (19); initial anemia in heart failure patients resolved in
a large proportion of the patients, and these patients did not
pose greater long-term risk compared with patients without
anemia at baseline. However, new-onset anemia is shown to
predict outcome in outpatients with heart failure (19,20).
Komajda et al. (20) found that a large decrease in hemo-
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sex, age, NYHA functional class, eGFR, BMI, diabetes mellitus, and lo
Abbreviations as in Tables 1 and 3.globin level during follow-up independently predicted mor-tality. Our data confirmed that patients with new-onset
anemia had poorer prognosis than patients without anemia
at any time, but after multivariate correction new-onset
anemia was not an independent predictor of all-cause
mortality. This could be due to lack of statistical power,
because the number of patients was low in this subgroup.
Sustained anemia, however, involving 12.1% of our pa-
tients completing all visits, independently predicted mortal-
ity, and no interaction with severe renal dysfunction and
advanced heart failure were found in this selected subgroup
of patients who completed all planned visits. This might
reflect that the cut point for anemia in heart failure patients
should not follow the WHO criteria but rather be slightly
lower, but alternative explanations might exist.
Lower baseline hemoglobin levels in the patients with
sustained anemia were associated with increased mortality;
thus the degree of anemia would probably identify patients
at especially high risk of mortality. This association was not
found in the nonanemic patients and among patients with
transient anemia. Go et al. (14) identified increased risk of
death in heart failure patients with hemoglobin levels below
13 g/dl. Thus, our data did not support specific anemia
treatment goal to exceed 13 g/dl.
The clinical implications of our findings might be impor-
tant. Baseline anemia was not an independent predictor of
all-cause mortality in heart failure patients with the worst
prognosis (i.e., advanced NYHA functional classes and
severe renal failure). In the selected population who were
able to attend subsequent visits, sustained anemia after
optimizing conventional heart failure treatment seemed to
predict mortality independently of renal function and
NYHA functional class. Such patients would be suitable for
randomized controlled trials that examine specific anemia
treatment in addition to conventional optimal treatment
and intense follow-up. However, if these trials would show
improved survival of specific anemia treatment, it is uncer-
tain whether the results would be valid and applicable for an
unselected outpatient population with heart failure.
Study limitations. This study presented data from an
existing heart failure registry. We were not able to evaluate
the quality of the data, and analyses were restricted to
existing data in the registry. The number of patients was
large, but subgroup analyses might have been underpow-
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this study design. Data on hospital stay would have given
important additional outcome information. Such analyses
were not possible, due to the low number of valid data on
hospital stay. Furthermore, adequate data on follow-up
symptoms, BNP/pro-BNP, and device therapy would have
supplemented our data concerning outcome. Arbitrary cat-
egorization of advanced heart failure and severe renal
function were used, because a low number of patients
presented with NYHA functional class IV or CKD class 4
and 5. Continuous worsening prognosis with decreasing
eGFR and increasing NYHA functional classes in our
material supported the arbitrary classification, which was
undertaken to increase statistical power in the subgroup
analyses.
Conclusions
Baseline anemia was predictive of all-cause mortality in this
study of outpatients with chronic heart failure; however, this
was not seen in those with advanced symptoms of heart
failure or severe renal failure at baseline. In the selected
population with valid follow-up data, sustained anemia after
optimizing heart failure treatment implied worse prognosis
independently of renal function and NYHA functional
class.
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